Testa vår nya webbplats och uppdaterade nyhetsrum för att ta del av aktuella nyheter, rapporter och mycket mer.
Eevia Health Plc receives multiple smaller sales orders in total EUR 30k
Eevia Health ("Eevia" or "The Company") received several smaller sales orders for multiple products from multiple Finnish and European customers for a combined value of just over EUR 30k.
Eevia does not issue a press release for smaller orders than EUR 10 k. However, the Company received multiple sales orders, which amounted to over EUR 30k, and would like to communicate the sales order income for this.
The orders came from a range of smaller customers and for multiple products. The customers are medium-sized organic food and beverage brands as well as contract manufacturers of consumer ready-made dietary supplements from Finland and Europe. There is an expectation that these orders will be repeated regularly in the future.
One of the orders was for FENO-CHAGA™ ORGANIC, which is an immunomodulating extract standardized on Beta-glucans and polyphenols. The FENO-CHAGA™ ORGANIC is made from wild-harvested chaga from Finland, a mushroom growing naturally on birch trees. The Eevia product stands out in terms of bioactivity and quality from the so-called MOG Chaga, which is Chaga from "Mycelium on Grain". This product is produced in-house in China and other countries and does not contain the same level of secondary metabolites as the wild chaga.
For further information, please contact:
Stein Ulve, CEO, Eevia Health Plc
Email: [email protected]
Telephone: +358 400 22 5967
INFORMATION ABOUT EEVIA HEALTH PLC
Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients in dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.
Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.
Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) EEVIA.
To learn more, please visit www.eeviahealth.com or follow Eevia Health on [email protected]
Eevia Health Plc
Marknadsplats: Spotlight stock market